1130P Tebentafusp (tebe) in an ongoing cohort of 72 French patients (pts) with metastatic uveal melanoma (mUM)
Léah Mailly-Giacchetti(Inserm), Manuel Rodrigues(Inserm), J-C. Thery(Centre Virchow-Villermé), Marc Pracht(Canadian Partnership Against Cancer), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), N. Litrowski, Sylvaine Renault(Institut Curie), Mathilde Saint‐Ghislain(Inserm), Leanne de Koning(Institut Curie), Hélène Martin(Centre Hospitalier Régional de Metz-Thionville), T. Ramtohul(Institut Curie), Sophie Piperno‐Neumann(Institut Curie), P-F. Combe(Pôle Léonard de Vinci), Vincent Servois(Institut Curie)
Cited by 1
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k